DOP071. Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies

Exposure Response

Mo1781 Tofacitinib Plasma Concentration Monitoring Is Not Needed for Optimization of Induction Therapy in Moderate to Severe Ulcerative Colitis: Results of Pooled Exposure-Response Analyses of Phase 3 Induction Studies

Gastroenterology ◽

10.1016/s0016-5085(16)32624-5 ◽

2016 ◽

Vol 150 (4) ◽

pp. S774

Author(s):

Arnab Mukherjee ◽

Shinichi Tsuchiwata ◽

Chenhui Deng ◽

Camille Vong ◽

Rujia Xie ◽

...

Keyword(s):

Ulcerative Colitis ◽

Plasma Concentration ◽

Induction Therapy ◽

Phase 3 ◽

Exposure Response

767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials

Gastroenterology ◽

10.1016/s0016-5085(16)30622-9 ◽

2016 ◽

Vol 150 (4) ◽

pp. S157 ◽

Cited By ~ 7

Author(s):

William Sandborn ◽

Bruce E. Sands ◽

Geert R. D'Haens ◽

Severine Vermeire ◽

Stefan Schreiber ◽

...

Keyword(s):

Ulcerative Colitis ◽

Randomized Controlled Trials ◽

Induction Therapy ◽

Controlled Trials ◽

Efficacy And Safety ◽

Phase 3 ◽

Two Phase ◽

Randomized Controlled

OP019. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjw019.018 ◽

2016 ◽

Vol 10 (suppl 1) ◽

pp. S15.1-S15 ◽

Cited By ~ 1

Keyword(s):

Ulcerative Colitis ◽

Induction Therapy ◽

Randomised Controlled Trials ◽

Controlled Trials ◽

Efficacy And Safety ◽

Phase 3 ◽

Randomised Controlled

Tu1859 CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH DURABLE RESPONSE TO USTEKINUMAB INDUCTION THERAPY: RESULTS FROM THE UNIFI PHASE 3 STUDIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS

Gastroenterology ◽

10.1016/s0016-5085(20)33646-5 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-1191

Author(s):

Katherine Li ◽

Feifei Yang ◽

Karen Hayden ◽

David Strawn ◽

Eric Wadman ◽

...

Keyword(s):

Ulcerative Colitis ◽

Molecular Characterization ◽

Induction Therapy ◽

Phase 3 ◽

Durable Response ◽

Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI

10.1055/s-0039-1691869 ◽

2019 ◽

Author(s):

BE Sands ◽

L Peyrin-Biroulet ◽

C Marano ◽

CD O'Brien ◽

H Zhang ◽

...

Keyword(s):

Ulcerative Colitis ◽

Phase 3 ◽

Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients

Gastroenterology ◽

10.1016/s0016-5085(17)32133-9 ◽

2017 ◽

Vol 152 (5) ◽

pp. S595-S596 ◽

Cited By ~ 1

Author(s):

Arnab Mukherjee ◽

Geert R. D'Haens ◽

William J. Sandborn ◽

Shinichi Tsuchiwata ◽

Camille Vong ◽

...

Keyword(s):

Ulcerative Colitis ◽

Phase 3 ◽

Exposure Response ◽

Maintenance Study

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00338-1 ◽

2021 ◽

Author(s):

David T Rubin ◽

Iris Dotan ◽

Aaron DuVall ◽

Yoram Bouhnik ◽

Graham Radford-Smith ◽

...

Keyword(s):

Ulcerative Colitis ◽

Induction Therapy ◽

Randomised Controlled Trials ◽

Controlled Trials ◽

Active Ulcerative Colitis ◽

Phase 3 ◽

Two Phase ◽

Randomised Controlled

Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies

Gastroenterology ◽

10.1016/s0016-5085(19)37953-3 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-442

Author(s):

Silvio Danese ◽

Bruce E. Sands ◽

Rupert W. Leong ◽

Hongyan Zhang ◽

Jewel Johanns ◽

...

Keyword(s):

Ulcerative Colitis ◽

Health Status ◽

General Health ◽

General Health Status ◽

Phase 3 ◽

748 Ustekinumab Improved Work Productivity in Patients With Moderate to Severe Ulcerative Colitis: Results From the Phase 3 UNIFI Induction and Maintenance Studies

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000592528.88422.70 ◽

2019 ◽

Vol 114 (1) ◽

pp. S438-S438

Author(s):

Chenglong Han ◽

Dominik Naessens ◽

Hongyan Zhang ◽

Jewel Johanns ◽

Colleen Marano ◽

...

Keyword(s):

Ulcerative Colitis ◽

Work Productivity ◽

Phase 3 ◽

646 Molecular Response to Ustekinumab in Moderate-to-Severe Ulcerative Colitis by Serum Protein and Colon Transcriptomic Analysis: Results From the UNIFI Phase 3 Maintenance Study

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000592120.98792.10 ◽

2019 ◽

Vol 114 (1) ◽

pp. S378-S378

Author(s):

Katherine Li ◽

Feifei Yang ◽

Karen Hayden ◽

David Strawn ◽

Eric Wadman ◽

...

Keyword(s):

Ulcerative Colitis ◽

Serum Protein ◽

Transcriptomic Analysis ◽

Molecular Response ◽

Phase 3 ◽

Maintenance Study